Bausch + Lomb discontinued its glaucoma eye-drop candidate BL1107 after a Phase 2 trial missed primary and secondary endpoints. The company had been evaluating the alpha-2B agonist in patients with primary open-angle glaucoma or ocular hypertension, with the program designed to improve visual sensitivity by Day 28. Following the reported failure, Bausch + Lomb said it will abandon further glaucoma development of BL1107 and pivot toward a sustained-release implant program associated with a recent Whitecap Biosciences acquisition. Clinical trial initiation is slated for 2028, with development planned in collaboration with Ripple Therapeutics’ controlled-release technology. The decision illustrates how ophthalmology portfolios remain multi-asset and indication-flexible, where a setback can trigger rapid reprioritization toward the next modality believed to have a better therapeutic window. It also highlights the risk of pathway-specific modality bets—here, topical drops versus implantable sustained delivery. For investors and partners, the key readthrough is that acquisition-backed assets can require quick course corrections when endpoint performance fails to justify continued spend.